Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomize...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Autores principales: Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431298/
https://ncbi.nlm.nih.gov/pubmed/27751729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.10.007
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares